PortalPublikationenPrevalence and impact of SARS-CoV-2 infection on maternal an...

Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project)

Standard

Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project). / Figueroa-Romero, Antía; Mendes, Anete; Mombo-Ngoma, Ghyslain; Mischlinger, Johannes; Esen, Meral; Vogler, Michael; Mazuze, Maura; Mombo-Nzamba, Lionel; Mbadinga, Benjamin; Sanz, Sergi; Ramharter, Michael; Saute, Francisco; Nhampossa, Tacilta; Menendez, Clara; González, Raquel.

in: BMJ OPEN, Jahrgang 13, Nr. 5, 22.05.2023, S. e067083.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Figueroa-Romero, A, Mendes, A, Mombo-Ngoma, G, Mischlinger, J, Esen, M, Vogler, M, Mazuze, M, Mombo-Nzamba, L, Mbadinga, B, Sanz, S, Ramharter, M, Saute, F, Nhampossa, T, Menendez, C & González, R 2023, 'Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project)', BMJ OPEN, Jg. 13, Nr. 5, S. e067083. https://doi.org/10.1136/bmjopen-2022-067083

APA

Figueroa-Romero, A., Mendes, A., Mombo-Ngoma, G., Mischlinger, J., Esen, M., Vogler, M., Mazuze, M., Mombo-Nzamba, L., Mbadinga, B., Sanz, S., Ramharter, M., Saute, F., Nhampossa, T., Menendez, C., & González, R. (2023). Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project). BMJ OPEN, 13(5), e067083. https://doi.org/10.1136/bmjopen-2022-067083

Vancouver

Figueroa-Romero A, Mendes A, Mombo-Ngoma G, Mischlinger J, Esen M, Vogler M et al. Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project). BMJ OPEN. 2023 Mai 22;13(5):e067083. https://doi.org/10.1136/bmjopen-2022-067083

Bibtex

@article{342b93af6bc5490699cbea5e5da35ff4,
title = "Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project)",
abstract = "INTRODUCTION: Pregnant women are currently considered a vulnerable population to SARS-CoV-2 infection, with increased risk of severe COVID-19, preterm birth and maternal mortality. There is, however, a paucity of data on the burden of maternal SARS-CoV-2 infection in sub-Saharan countries. The objective of this study is to determine the prevalence and health effects of maternal SARS-CoV-2 infection in selected sites from Gabon and Mozambique.METHODS AND ANALYSIS: MA-CoV (MAternal CoVid) is an observational, multicentre prospective cohort study where 1000 pregnant women (500 per country) will be enrolled at the antenatal clinic visits. Participants will undergo monthly follow-up at each antenatal care visit, delivery and postpartum visit. The primary study outcome is the prevalence of SARS-CoV-2 infection during pregnancy. The clinical presentation of COVID-19 in pregnancy will also be characterised, and incidence of infection during pregnancy will be evaluated, as well as the risk factors of maternal and neonatal morbidity and mortality associated with SARS-CoV-2 infection and the risk of mother to child transmission of SARS-CoV-2. SARS-CoV-2 infection screening will be performed through PCR diagnosis.ETHICS AND DISSEMINATION: The protocol was reviewed and approved by the Comit{\'e} National d'{\'E}thique pour la Recherche au Gabon, Comit{\'e} Nacional de Bio{\'e}tica para Sa{\'u}de de Mo{\c c}ambique and the Ethics Committee of the Hospital Clinic of Barcelona (Spain). Project results will be presented to all stakeholders and published in open access journals.TRIAL REGISTRATION NUMBER: NCT05303168.",
keywords = "Infant, Child, Female, Infant, Newborn, Humans, Pregnancy, COVID-19/epidemiology, SARS-CoV-2, Infant Health, Prevalence, Prospective Studies, Premature Birth/epidemiology, Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious/epidemiology, Multicenter Studies as Topic",
author = "Ant{\'i}a Figueroa-Romero and Anete Mendes and Ghyslain Mombo-Ngoma and Johannes Mischlinger and Meral Esen and Michael Vogler and Maura Mazuze and Lionel Mombo-Nzamba and Benjamin Mbadinga and Sergi Sanz and Michael Ramharter and Francisco Saute and Tacilta Nhampossa and Clara Menendez and Raquel Gonz{\'a}lez",
note = "{\textcopyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2023",
month = may,
day = "22",
doi = "10.1136/bmjopen-2022-067083",
language = "English",
volume = "13",
pages = "e067083",
journal = "BMJ OPEN",
issn = "2044-6055",
publisher = "British Medical Journal Publishing Group",
number = "5",

}

RIS

TY - JOUR

T1 - Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations: protocol of a multicentre prospective cohort study (MA-CoV project)

AU - Figueroa-Romero, Antía

AU - Mendes, Anete

AU - Mombo-Ngoma, Ghyslain

AU - Mischlinger, Johannes

AU - Esen, Meral

AU - Vogler, Michael

AU - Mazuze, Maura

AU - Mombo-Nzamba, Lionel

AU - Mbadinga, Benjamin

AU - Sanz, Sergi

AU - Ramharter, Michael

AU - Saute, Francisco

AU - Nhampossa, Tacilta

AU - Menendez, Clara

AU - González, Raquel

N1 - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2023/5/22

Y1 - 2023/5/22

N2 - INTRODUCTION: Pregnant women are currently considered a vulnerable population to SARS-CoV-2 infection, with increased risk of severe COVID-19, preterm birth and maternal mortality. There is, however, a paucity of data on the burden of maternal SARS-CoV-2 infection in sub-Saharan countries. The objective of this study is to determine the prevalence and health effects of maternal SARS-CoV-2 infection in selected sites from Gabon and Mozambique.METHODS AND ANALYSIS: MA-CoV (MAternal CoVid) is an observational, multicentre prospective cohort study where 1000 pregnant women (500 per country) will be enrolled at the antenatal clinic visits. Participants will undergo monthly follow-up at each antenatal care visit, delivery and postpartum visit. The primary study outcome is the prevalence of SARS-CoV-2 infection during pregnancy. The clinical presentation of COVID-19 in pregnancy will also be characterised, and incidence of infection during pregnancy will be evaluated, as well as the risk factors of maternal and neonatal morbidity and mortality associated with SARS-CoV-2 infection and the risk of mother to child transmission of SARS-CoV-2. SARS-CoV-2 infection screening will be performed through PCR diagnosis.ETHICS AND DISSEMINATION: The protocol was reviewed and approved by the Comité National d'Éthique pour la Recherche au Gabon, Comité Nacional de Bioética para Saúde de Moçambique and the Ethics Committee of the Hospital Clinic of Barcelona (Spain). Project results will be presented to all stakeholders and published in open access journals.TRIAL REGISTRATION NUMBER: NCT05303168.

AB - INTRODUCTION: Pregnant women are currently considered a vulnerable population to SARS-CoV-2 infection, with increased risk of severe COVID-19, preterm birth and maternal mortality. There is, however, a paucity of data on the burden of maternal SARS-CoV-2 infection in sub-Saharan countries. The objective of this study is to determine the prevalence and health effects of maternal SARS-CoV-2 infection in selected sites from Gabon and Mozambique.METHODS AND ANALYSIS: MA-CoV (MAternal CoVid) is an observational, multicentre prospective cohort study where 1000 pregnant women (500 per country) will be enrolled at the antenatal clinic visits. Participants will undergo monthly follow-up at each antenatal care visit, delivery and postpartum visit. The primary study outcome is the prevalence of SARS-CoV-2 infection during pregnancy. The clinical presentation of COVID-19 in pregnancy will also be characterised, and incidence of infection during pregnancy will be evaluated, as well as the risk factors of maternal and neonatal morbidity and mortality associated with SARS-CoV-2 infection and the risk of mother to child transmission of SARS-CoV-2. SARS-CoV-2 infection screening will be performed through PCR diagnosis.ETHICS AND DISSEMINATION: The protocol was reviewed and approved by the Comité National d'Éthique pour la Recherche au Gabon, Comité Nacional de Bioética para Saúde de Moçambique and the Ethics Committee of the Hospital Clinic of Barcelona (Spain). Project results will be presented to all stakeholders and published in open access journals.TRIAL REGISTRATION NUMBER: NCT05303168.

KW - Infant

KW - Child

KW - Female

KW - Infant, Newborn

KW - Humans

KW - Pregnancy

KW - COVID-19/epidemiology

KW - SARS-CoV-2

KW - Infant Health

KW - Prevalence

KW - Prospective Studies

KW - Premature Birth/epidemiology

KW - Infectious Disease Transmission, Vertical

KW - Pregnancy Complications, Infectious/epidemiology

KW - Multicenter Studies as Topic

U2 - 10.1136/bmjopen-2022-067083

DO - 10.1136/bmjopen-2022-067083

M3 - SCORING: Journal article

C2 - 37217271

VL - 13

SP - e067083

JO - BMJ OPEN

JF - BMJ OPEN

SN - 2044-6055

IS - 5

ER -